Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 4/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | NPY4R | P50391 | 6/20 | 0.48 |
| ▸ | NPY1R | P25929 | 3/20 | 0.48 |
| ▸ | NPY2R | P49146 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675898 | 1.00 | KISS1R (0.50) | KISS1RACENPY4RNPY1RNPY2R | |
| SCHEMBL30656932 | 0.94 | KISS1R (0.57) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30252365 | 0.92 | MME (0.51) | KISS1RACENPY4RNPY1RNPY2R | |
| SCHEMBL29697013 | 0.92 | MME (0.51) | KISS1RACENPY4RNPY1RNPY2R | |
| SCHEMBL31028236 | 0.91 | OPRD1 (0.49) | KISS1RACENPY4RNPY1RNPY2R | |
| SCHEMBL29528212 | 0.88 | OPRD1 (0.57) | KISS1RACENPY4RNPY1RNPY2R | |
| SCHEMBL29409591 | 0.86 | OPRD1 (0.54) | NPY4RNPY1RNPY2ROPRD1OPRM1 | |
| SCHEMBL30656936 | 0.86 | OPRM1 (0.53) | KISS1RNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30799540 | 0.86 | OPRD1 (0.54) | KISS1ROPRD1OPRM1OPRK1 | |
| SCHEMBL31406596 | 0.85 | KISS1R (0.53) | KISS1RACENPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | KISS1R 3444/4885ACE 531/4885NPY4R 86/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | KISS1R 1372/4885ACE 988/4885NPY4R 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.